



2FW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Fridovich-Keil, et al.

Confirmation No.: 2108

Group Art Unit: 1636

Serial No.: 10/781,012

Examiner: TBD

Filed: 2/18/04

Docket No.: 050508-1200

For: Mammalian Cell Lines Specifically Deficient in O-Linked Glycosylation

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This information disclosure statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, and specifically:

- ☒ under 37 CFR 1.97(b), or
(within Three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either a:
☐ Statement Under 37 C.F.R. 1.97(e), or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before the final office action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with a:
☐ Statement under 37 CFR 1.97(e), and
☐ a \$180.00 petition fee set forth in 37 CFR 1.17(p).
(Filed after final office action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Enclosed is a check in the amount of \$.

Enclosed is Credit Card Payment Form (PTO-2038) in the amount of \$.

Please charge \$. to deposit account . At any time during the pendency of this application, please charge any fees required to Deposit Account 20-0778 pursuant to 37 CFR 1.25. The Commissioner is hereby requested to credit any overpayment to Deposit Account No. 20-0778.

- ☒ Applicant(s) submit herewith *Form PTO 1449A - Information Disclosure Statement by Applicant* together with copies (where required) of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may or may not be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. As required by 37 C.F.R. §1.98(a), a legible copy of each document is provided.
- ☐ A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form 1449, as presently understood by the individual(s) designated in 37 CFR 1.56(c) most knowledgeable about the content is given on the attached sheet, or where a foreign language patent is cited in a search report or other action by a foreign patent office in a counterpart foreign application, an English language version of the search report or action which indicates the degree of relevance found by the foreign office is listed on the form PTO 1449 and is enclosed herewith.


The following rights are reserved by the Applicant(s): the right to establish the patentability of the claimed invention over any of the listed documents should they be applied as reference, and/or the right to prove that some of these documents may not be prior art, and/or the right to prove that some of these documents may not be enabling for the teachings they purport to offer.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present application does not exist. Any statements or identifications regarding the relevance of any portion(s) of cited references should not be construed as a representation that the most relevant portion(s) have been identified, and the absence of such statements or identifications should not be construed as representations that there are no relevant portion(s). The Examiner is specifically requested not to rely solely on the materials submitted herewith. The Examiner is requested to conduct an independent and thorough review of the documents, and to form independent opinions as to their significance.

It is requested that the information disclosed herein be made of record in this application and that the Examiner initial and return a copy of the enclosed PTO-1449 to indicate the documents have been considered.

Respectfully Submitted,


THOMAS, KAYDEN, HORSTEMEYER
& RISLEY, L.L.P.

By: 
Christopher B. Linder, Reg. No. 47,751

100 Galleria Parkway, Suite 1750
Atlanta, Georgia 30339-5948
770-933-9500

CERTIFIED MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "First Class Mail," in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 12, 2005.


Signature

EXPRESS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner for Patent, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA, on

Express Mail No. _____

Signature

Form PTO-1449


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.

050508-1200

Serial No.

10/781,012

Applicant

Fridovich-Keil, et al.

Filing Date

2/18/04

Group

1636

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A						
	B						
	C						
	D						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	E							
	F							
	G							
	H							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

I	Holden, HM et al., Structure and Function of Enzymes of the Leloir Pathway for Galactose Metabolism. The Journal of Biological Chemistry, November 2003, Vol. 278, No. 45, pages 43885-43888.
J	Kozarsky, K., et al., Use of a Mutant cell Line to Study the Kinetics and Function of O-linked Glycosylation of Low Density Lipoprotein Receptors, Proc. Natl. Acad. Sci. USA, June 1988, Vol. 85, pages 4335-4339.
K	Shulz, J.M., et al. Determinants of Function and Substrate Specificity in Human UDP-galactose 4'-epimerase. The Journal of Biological Chemistry, July 2004, Vol. 279, No. 31, pages 32796-32803.
L	Duade, N., et al., Molecular Cloning, Characterization, and Mapping of a Full-Length cDNA Encoding Human UDP-Galactose 4'-Epimerase, Biochemical and Molecular Medicine, Oct. 1995, Vol. 56, No. 1, pages 1-7, especially Figure 1 and page 3.
M	Thoden, J.B., et al., Crystal Structures of the Oxidized and Reduced Forms of UDP-galactose 4-Epimerase Isolated from Escherichia coli., Biochemistry, Feb. 1996, Vol. 35, No. 8, pages 2557-2566, especially page 2558.

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE:

DATE CONSIDERED:



CERTIFICATE OF MAILING

I hereby certify that the below listed items are being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

**Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**

on 5/12/05.

Sara Rogers
Name: Sara Rogers

In re: Fridovich-Keil, et al.

Serial No.: 10/781,012

Docket No.: 050508-1200

Filing Date: February 18, 2004

Group No.: 1636

For: Mammalian Cell Lines Specifically Deficient in O-Linked Glycosylation

The following is a list of documents enclosed:

Return Postcard
Information Disclosure Statement based on International Search Report
Statement Under 37 C.F.R. § 1.97(e)
IDS/Form 1449
International Search Report Form PCT/ISA/220 and Written Opinion
Prior Art (5)

Further, the Commissioner is authorized to charge Deposit Account No. 20-0778 for any additional fees required. The Commissioner is requested to credit any excess fee paid to Deposit Account No. 20-0778.